In an era of intense political rhetoric regarding government waste, the U.S. healthcare system faces a hidden, systematic crisis. While federal officials and political movements like the Department of Government Efficiency (DOGE) focus on broad accusations of fraud—often scapegoating immigrant communities and "woke ideology"—a deeper, more clinical issue has taken root. A comprehensive investigation by The 74 into 275 million Medicaid billing records reveals that the autism therapy industry has been transformed into a $7 billion goldmine for private equity, often at the expense of the very children it claims to serve.
The therapy in question, Applied Behavior Analysis (ABA), has become the industry standard for autism treatment. However, it is an approach increasingly mired in controversy, with critics—including many autistic adults—labeling it as traumatizing and ineffective. As federal, state, and private funds flow into this sector with minimal oversight, the convergence of aggressive financial practices and questionable clinical methods has created a landscape where profit margins are prioritized over patient well-being.
The Financialization of Autism Therapy
Between 2019 and 2024, Medicaid spending on the six most common ABA billing codes surged by 381%, ballooning from $400 million annually to nearly $2 billion. This explosive growth did not occur in a vacuum; it was fueled by the entry of private equity firms, which have aggressively acquired, consolidated, and scaled therapy providers into national chains.
Unlike publicly traded companies, private equity firms operate in the shadows, shielded from the transparency requirements that govern other sectors. Their model is straightforward: acquire a steady stream of revenue, optimize for short-term profit through aggressive billing, and eventually exit the investment. In the context of autism therapy, this has meant prioritizing high-intensity, high-cost treatment plans that maximize billable hours, regardless of the child’s actual therapeutic needs.
A Chronology of Expansion and Exploitation
The trajectory of the ABA industry can be traced back to a concerted, grassroots lobbying effort initiated in the mid-2000s.
- 2007: Driven by the personal story of Lorri Unumb, who fought to secure insurance coverage for her autistic son, South Carolina became the first state to mandate insurance coverage for ABA. This marked the birth of "Ryan’s Law."
- 2014: The Obama administration mandated that Medicaid plans must cover autism treatments, opening the floodgates for public funding.
- 2015–2024: Private equity firms recognized the potential of this guaranteed, government-backed revenue stream. During this decade, over 574 individual sites were acquired by private equity-backed entities, according to data from Brown University.
- 2022–Present: Federal audits by the Office of the Inspector General (OIG) began revealing massive discrepancies in billing. Investigations in red and blue states alike highlighted a "purple problem": systemic billing for unrendered services, "copy-paste" treatment notes, and the exclusion of evidence-based educational supports.
Supporting Data: The Cost of Profit
The financial data paints a stark picture of an industry detached from clinical reality. Over six years, Medicaid spent $7 billion on ABA therapy—an amount that dwarfs the $6 billion spent over the past two decades on the Autism CARES Act, which funds research and support programs intended to actually improve the quality of life for autistic individuals.
The consolidation of the industry has resulted in a market where 15 of the top providers are owned by private equity, accounting for over $1.5 billion in billing in just the last few years. The case of Centria Healthcare is emblematic. After being acquired by private equity, it became the nation’s largest Medicaid biller, despite being the subject of multiple investigations, lawsuits, and allegations of abuse—including footage of staff abusing a child. While the company has denied these claims, the financial structure of private equity ensures that the investment firms behind such providers remain largely insulated from the legal and reputational fallout of these scandals.
Clinical Concerns and Ethical Roots
The core of the backlash against ABA lies in its history and its methodology. Pioneered by Ole Ivar Lovaas in the 1960s, the practice relies on a system of rewards and punishments to "extinguish" behaviors deemed "abnormal." Notably, Lovaas also utilized these same behavioral conditioning techniques to develop conversion therapy for LGBTQ individuals—a practice now universally condemned as abusive.
Recent research, including a 2018 study of 460 autistic adults and a 2024 analysis from major universities, indicates that individuals who undergo ABA are 30% more likely to experience mental health hospitalizations compared to those who do not. The therapy’s insistence on compliance often ignores the underlying sensory and emotional needs of the child.
Furthermore, auditors have flagged that many children are kept in standalone ABA centers for up to 40 hours a week, effectively being denied their legal right to an integrated public education. In one egregious case cited in an Indiana audit, a child was kept in full-time ABA for years, missing out on critical academic instruction, while the provider billed the state for hundreds of thousands of dollars.
Official Responses and Industry Defense
The industry’s response to these findings has been consistent: distinguish "bad actors" from the "ethical" majority. Lorri Unumb, now CEO of the Council of Autism Service Providers, maintains that the vast majority of ABA providers are doing vital, life-changing work. She argues that fraud should be punished, but that the focus on bad actors unfairly stigmatizes a necessary medical service.
Conversely, investment firms like Blackstone, which previously owned the Center for Autism and Related Disorders (CARD), have framed their involvement as a response to market pressures. Blackstone noted that their exit and the subsequent restructuring of the company were the result of a "perfect storm" of labor shortages and reimbursement issues, rather than a failure of their business model.
However, critics such as Dr. Ari Ne’Eman, a former director of the Autistic Self-Advocacy Network, argue that private equity is not "corrupting" a previously pristine field; rather, it was drawn to the industry precisely because of its existing flaws—namely, the lack of regulatory oversight and the industry’s ability to define its own standards.
The Road Ahead: Implications for Policy
As the second Trump administration and federal agencies look to cut Medicaid costs, there is a legitimate fear among disability advocates that the wrong lessons will be learned. The current political environment threatens to slash services entirely, potentially harming children who truly need support, while failing to address the structural incentives that make the ABA industry so lucrative for investors.
The failure to implement independent, third-party oversight—as seen in the recent Colorado legislation, which was signed into law despite concerns that it further empowered industry-led boards—suggests that the cycle of profit-seeking will continue. For families, the implications are profound. They are often told that ABA is their child’s "only chance" for a normal life, a narrative that effectively traps them in a high-cost, low-accountability system.
If the goal is truly to stop government waste and improve outcomes for autistic children, policy must shift toward:
- Joint Liability: Implementing regulations that hold private equity parent companies legally and financially responsible for the actions of their acquired clinics.
- Independent Oversight: Mandating that state licensing boards include independent mental health professionals and autistic individuals, rather than relying on industry-created certifications.
- Educational Integration: Enforcing the right of autistic children to receive academic instruction in inclusive school settings, rather than allowing therapy centers to act as de facto, unregulated schools.
- Evidence-Based Funding: Redirecting Medicaid funds toward therapies and support systems that have demonstrated effectiveness and prioritize the autonomy and mental health of the individual.
The current situation is a warning: when healthcare is treated as an asset class to be flipped, the patients—particularly vulnerable children—become the collateral damage in a race for returns. Without meaningful reform, the autism therapy industry will continue to expand, leaving a trail of traumatized children and squandered public resources in its wake.
